The European Medicines Agency Review of Abiraterone for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Adult Men After Docetaxel Chemotherapy and in Chemotherapy-Naïve Disease: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use

On September 5, 2011, abiraterone was approved in the European Union in combination with prednisone or prednisolone for the treatment of metastatic castration-resistant prostate cancer (CRPC) in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen. On December 18...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Gravanis, Iordanis, Lopez, Arantxa Sancho, Hemmings, Robert James, Jiménez, Jorge Camarero, Garcia-Carbonero, Rocio, Gallego, Isabel García, Giménez, Elena Valencia, O'Connor, Daniel, Giuliani, Rosa, Salmonson, Tomas, Pignatti, Francesco
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2013
Assuntos:
Regulatory Issues: EMA
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3780635/
https://ncbi.nlm.nih.gov/pubmed/23966222
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2013-0092
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados